Protalix BioTherapeutics (PLX) – Major News
-
Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS
-
Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.16
-
Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
-
Protalix BioTherapeutics (PLX) Tops Q3 EPS by 8c
-
Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
-
Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
-
Protalix BioTherapeutics (PLX) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $48.7M
-
Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c
-
Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat
-
Protalix BioTherapeutics (PLX) Receives FDA CRL for Pegunigalsidase Alfa
-
Protalix BioTherapeutics (PLX) Reports Q3 Revenues Beat
-
Protalix BioTherapeutics (PLX) Tops Q2 EPS by 7c
-
Protalix BioTherapeutics (PLX) Tops Q1 EPS by 40c, Revenues Beat
-
Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
-
Protalix BioTherapeutics (PLX) Misses Q3 EPS by 10c
-
Protalix BioTherapeutics (PLX) Names Dror Bashan President/CEO
-
Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre
-
Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
-
Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
-
Protalix (PLX) Sells ELELYSO Collaboration Stake to Pfizer (PFE)
-
Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
-
Protalix BioTherapeutics (PLX) Names New CEO
-
Protalix BioTherapeutics (PLX) CEO David Aviezer, Ph.D., Plans Retirement
-
Protalix Biotherapeutics, Inc. (PLX) Posts Q4 Loss of 12c/Share
-
Protalix (PLX) Affirms Talks, Engages Citigroup as Advisor
-
Protalix (PLX) Receives FDA CRL On Taliglucerase
-
Protalix (PLX) Reports Q3 EPS of 3c
-
Protalix (PLX) Enters Deal With Pfizer (PFE) To Develop Gaucher's Disease Treatment
Back to PLX Stock Lookup